We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery.
- Authors
Yang, Yeon-Suk; Kim, Jung-Min; Xie, Jun; Chaugule, Sachin; Lin, Chujiao; Ma, Hong; Hsiao, Edward; Hong, Jaehyoung; Chun, Hyonho; Shore, Eileen M.; Kaplan, Frederick S.; Gao, Guangping; Shim, Jae-Hyuck
- Abstract
Heterotopic ossification is the most disabling feature of fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder for which there is currently no prevention or treatment. Most patients with this disease harbor a heterozygous activating mutation (c.617 G > A;p.R206H) in ACVR1. Here, we identify recombinant AAV9 as the most effective serotype for transduction of the major cells-of-origin of heterotopic ossification. We use AAV9 delivery for gene replacement by expression of codon-optimized human ACVR1, ACVR1R206H allele-specific silencing by AAV-compatible artificial miRNA and a combination of gene replacement and silencing. In mouse skeletal cells harboring a conditional knock-in allele of human mutant ACVR1 and in patient-derived induced pluripotent stem cells, AAV gene therapy ablated aberrant Activin A signaling and chondrogenic and osteogenic differentiation. In Acvr1(R206H) knock-in mice treated locally in early adulthood or systemically at birth, trauma-induced endochondral bone formation was markedly reduced, while inflammation and fibroproliferative responses remained largely intact in the injured muscle. Remarkably, spontaneous heterotopic ossification also substantially decreased in in Acvr1(R206H) knock-in mice treated systemically at birth or in early adulthood. Collectively, we develop promising gene therapeutics that can prevent disabling heterotopic ossification in mice, supporting clinical translation to patients with fibrodysplasia ossificans progressiva. Fibrodysplasia ossificans progressiva is an ultra-rare genetic disorder with progressive heterotopic ossification. Yang et al develop different gene therapy approaches and show their efficacy in mouse models and in human induced pluripotent stem cells.
- Subjects
PLURIPOTENT stem cells; FIBRODYSPLASIA ossificans progressiva; DYSPLASIA; HETEROTOPIC ossification; INDUCED pluripotent stem cells; GENETIC disorders
- Publication
Nature Communications, 2022, Vol 13, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-022-33956-9